Anixa Biosciences, Inc.
ANIXStock
$3.32−0.31%52W
Market Cap$123.16M
P/E—
Div yield—
Beta0.56
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-8.36%
Price vs S&P 500 (4W)29.03%
VGM Score39.96
Market Capitalization$123.16M
Earnings Surprise History
Q2 26-0.07est. -0.09
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.10
4.10
4.11
4.10
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ANIXAnixa Biosciences, Inc. | F | — | B | $3.32 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Anixa Biosciences develops cancer vaccines and immunotherapies targeting major oncology indications including breast, ovarian, lung, colon, and prostate cancers. The company operates two primary therapeutic segments: cancer vaccines for treatment and prevention, and CAR-T therapies including lira-cel for ovarian cancer through subsidiary Certainty Therapeutics. Anixa's approach addresses critical unmet needs in oncology through multiple immunotherapy modalities.